Meidong Zhu1,2,3, Wijeyanthy Wijeyakumar1,2,3, Adil R Syed1,2,3, Nichole Joachim1,2, Thomas Hong1,2, Geoffrey K Broadhead1,2,3, Haitao Li1,2, Kehui Luo4, Andrew Chang5,6,7. 1. Sydney Retina Clinic & Day Surgery, Level 13, Park House, 187 Macquarie Street, Sydney, NSW, 2000, Australia. 2. Sydney Institute of Vision Science, Sydney, Australia. 3. Save Sight Institute, The University of Sydney, Sydney, Australia. 4. Department of Statistics, Faculty of Science and Engineering, Macquarie University, Sydney, Australia. 5. Sydney Retina Clinic & Day Surgery, Level 13, Park House, 187 Macquarie Street, Sydney, NSW, 2000, Australia. achang@sydneyretina.com.au. 6. Sydney Institute of Vision Science, Sydney, Australia. achang@sydneyretina.com.au. 7. Save Sight Institute, The University of Sydney, Sydney, Australia. achang@sydneyretina.com.au.
Abstract
PURPOSE: To assess changes in vision-related quality of life (VR-QoL) among patients with treatment-resistant neovascular age-related macular degeneration (nAMD) following intravitreal aflibercept treatment over 48 weeks. METHODS: We conducted a prospective study in which 49 patients with nAMD resistant to anti-vascular endothelial growth factor therapy were switched to intravitreal aflibercept. Patients were treated with three loading doses every 4 weeks followed by injections every 8 weeks, for a total of 48 weeks. Ophthalmic examinations performed at each visit included best-corrected visual acuity (BCVA) and central macular thickness (CMT) measurement. The National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) was used to assess VR-QoL at baseline and weeks 24 and 48. Changes in NEI VFQ-25 composite and subscale scores were analyzed using paired t tests. The relationship between the change in VR-QoL and changes in BCVA and CMT, and the impact of the better-seeing eye (BSE, defined as the eye reading the greater number of letters at baseline) vs. the worse-seeing eye (WSE, the fellow eye to the BSE) were assessed. RESULTS: Mean NEI VFQ-25 composite scores improved significantly at weeks 24 and 48 compared to baseline (4.5 ± 9.2 and 4.4 ± 11.8, respectively, all p < 0.01). Among subscales, general vision and near and distance activities showed significant improvements at weeks 24 and 48 (all p < 0.05). Improvement in the NEI VFQ-25 composite score was significantly associated with increased BCVA at week 48 (β coefficient = 0.43, p = 0.029), but not with change in CMT (β coefficient = -0.007, p = 0.631). There was no association between VR-QoL changes and BSE or WSE. CONCLUSION: Despite previous anti-VEGF treatment in this cohort, overall VR-QoL improved following aflibercept therapy over 48 weeks. This improvement was related to improved vision in treatment eyes regardless of whether they were the BSE or WSE.
PURPOSE: To assess changes in vision-related quality of life (VR-QoL) among patients with treatment-resistant neovascular age-related macular degeneration (nAMD) following intravitreal aflibercept treatment over 48 weeks. METHODS: We conducted a prospective study in which 49 patients with nAMD resistant to anti-vascular endothelial growth factor therapy were switched to intravitreal aflibercept. Patients were treated with three loading doses every 4 weeks followed by injections every 8 weeks, for a total of 48 weeks. Ophthalmic examinations performed at each visit included best-corrected visual acuity (BCVA) and central macular thickness (CMT) measurement. The National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) was used to assess VR-QoL at baseline and weeks 24 and 48. Changes in NEI VFQ-25 composite and subscale scores were analyzed using paired t tests. The relationship between the change in VR-QoL and changes in BCVA and CMT, and the impact of the better-seeing eye (BSE, defined as the eye reading the greater number of letters at baseline) vs. the worse-seeing eye (WSE, the fellow eye to the BSE) were assessed. RESULTS: Mean NEI VFQ-25 composite scores improved significantly at weeks 24 and 48 compared to baseline (4.5 ± 9.2 and 4.4 ± 11.8, respectively, all p < 0.01). Among subscales, general vision and near and distance activities showed significant improvements at weeks 24 and 48 (all p < 0.05). Improvement in the NEI VFQ-25 composite score was significantly associated with increased BCVA at week 48 (β coefficient = 0.43, p = 0.029), but not with change in CMT (β coefficient = -0.007, p = 0.631). There was no association between VR-QoL changes and BSE or WSE. CONCLUSION: Despite previous anti-VEGF treatment in this cohort, overall VR-QoL improved following aflibercept therapy over 48 weeks. This improvement was related to improved vision in treatment eyes regardless of whether they were the BSE or WSE.
Authors: Christoph Hirneiss; Aljoscha S Neubauer; Carolin A Gass; Ingrid W Reiniger; Siegfried G Priglinger; Anselm Kampik; Christos Haritoglou Journal: Br J Ophthalmol Date: 2006-10-31 Impact factor: 4.638
Authors: Neil M Bressler; Tom S Chang; Ivan J Suñer; Jennifer T Fine; Chantal M Dolan; James Ward; Tsontcho Ianchulev Journal: Ophthalmology Date: 2010-03-02 Impact factor: 12.079
Authors: Li Ming Dong; Ashley L Childs; Carol M Mangione; Eric B Bass; Neil M Bressler; Barbara S Hawkins; Marta J Marsh; Päivi Miskala; Harrris A Jaffee; Lee A McCaffrey Journal: Am J Ophthalmol Date: 2004-07 Impact factor: 5.258
Authors: Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth Journal: Ophthalmology Date: 2012-10-17 Impact factor: 12.079
Authors: Robert P Finger; Vincent Daien; Bora M Eldem; James S Talks; Jean-Francois Korobelnik; Paul Mitchell; Taiji Sakamoto; Tien Yin Wong; Krystallia Pantiri; Joao Carrasco Journal: BMC Ophthalmol Date: 2020-07-17 Impact factor: 2.209
Authors: Theodoros Empeslidis; Matthew Storey; Theodoros Giannopoulos; Vassileios Konidaris; Paris G Tranos; Evangelia S Panagiotou; Irini C Voudouragkaki; Anastasios G Konstas Journal: Adv Ther Date: 2019-05-17 Impact factor: 3.845